

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of
Gerd GEISLINGER et al.

Serial No.: Unassigned

Filed: December 7, 2001

For: USE OF VERAPAMIL AND VERAPAMIL DERIVATIVES FOR PRODUCING
MEDICAMENTS WITH AN INHIBITING EFFECT ON β -GLUCURONIDASE IN
HUMAN TISSUE

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-identified application, Applicants respectfully
request that the following amendments be entered into the application:

IN THE CLAIMS:

Please replace claims 3 through 9 as originally filed with the amended claims 3
through 9 as follows:

--3. (Amended) Use according to claim 1, characterised in that the R-
enantiomers are used in pure form or, in comparison with the racemate, in enriched form.

B7
4. (Amended) Use according to claim 1, characterised in that the
glucuronidase inhibitor is used, with suitable pharmacologically compatible adjuvants,
orally or parenterally (in normally liberating or controlled liberating form.)

5. (Amended) Use according to claim 1, characterised in that the
glucuronidase inhibitor is used alone for the inhibition of β -glucuronidase in diseased tissue
in order to prevent the progress of the disease, e.g. by inhibition of the tumour progression
or the metastasis formation.